Effect of two hydrophobic polymers on the release of gliclazide from their matrix tablets.
Gliclazide is an oral hypoglycemic agent, indicated in non insulin dependent diabetes mellitus and in patients with diabetic retinopathy. It has good tolerability and is a short acting sulfonyl urea that requires large dose to maintain the blood glucose level. So development of a sustained release formulation of gliclazide (GLZ) is required for better patient compliance. This study was conducted to assess the effects of different drug polymer ratios on the release profile of gliclazide from the matrix. Oral matrix tablets of gliclazide were prepared by hot melt method, using pure and blended mixture of glyceryl monostearate (GMS) and stearic acid (SA) in different ratios. In vitro release pattern was studied for 8 h in phosphate buffer media (pH 7.4). Different kinetic models including zero order, first order, Higuchi and Peppas were applied to evaluate drug release behavior. Drug excipient compatibility was evaluated by scanning with DSC and FTIR. Higuchi model was found the most appropriate model for describing the release profile of GLZ and non-Fickian release was found predominant mechanism of drug release. The release of drug from the matrix was greatly controlled by GMS while SA appeared to facilitate the release of drug from matrix tablets. FTIR results showed no chemical interaction between drug and the polymers, and DSC results indicated amorphous state of GLZ and polymers without significant complex formation. The results indicate that matrix tablets of gliclazide using glyceryl monostearate and stearic acid showed marked sustained release properties.
University College of Pharmacy, University of the Punjab, Lahore, Pakistan. dr.talibhussain@hotmail.com
Talib
T
Hussain
Tariq
T
Saeed
Ahmad M
AM
Mumtaz
Zeeshan
Z
Javaid
Khizar
K
Abbas
Azeema
A
Awais
Hafiz Arfat
HA
Idrees
D000284:Administration, Oral; D002021:Buffers; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry*; D005907:Gliclazide / Q000008:administration & dosage / Q000737:chemistry*; D005989:Glycerides / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D057927:Hydrophobic and Hydrophilic Interactions; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry*; D007700:Kinetics; D008956:Models, Chemical; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013229:Stearic Acids / Q000737:chemistry*; D013607:Tablets; D013678:Technology, Pharmaceutical / Q000379:methods
D002021:Buffers; D003692:Delayed-Action Preparations; D005079:Excipients; D005989:Glycerides; D007004:Hypoglycemic Agents; D013229:Stearic Acids; D013607:Tablets; C048159:glyceryl monostearate; C031183:stearic acid; D005907:Gliclazide